GlassScriptPhysician profile
Richard Urbanek
NPI 1043286065
$4,783.68
in general payments reported to CMS, 2019-2025
34 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $790 · 2021: $456 · 2022: $591 · 2023: $283 · 2024: $627 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,133.29 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Genzyme Corporation | $621.73 | 2019-2024 | |
| Lilly USA, LLC | $369.85 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $331.90 | 2019-2025 | |
| Merz North America, INC. | $295.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $257.18 | 2020-2025 | Odomzo, Blu-U |
| Dermavant Sciences, INC. | $217.00 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $175.33 | 2019-2025 | Nemluvio |
| Amgen INC. | $134.63 | 2023-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $121.33 | 2024-2025 | Zoryve |
| Janssen Scientific Affairs, LLC | $101.90 | 2019 | |
| Pfizer INC. | $98.37 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $92.64 | 2019-2021 | |
| Celgene Corporation | $91.00 | 2019 | |
| Abbvie INC. | $78.31 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $72.07 | 2020-2021 | |
| Organon LLC | $70.34 | 2025 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $69.15 | 2024-2025 | Valchlor |
| Leo Pharma INC. | $59.91 | 2022-2025 | Adbry, Anzupgo |
| Incyte Corporation | $47.02 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $45.01 | 2023-2025 | Sotyktu |
| Botanix Sb INC | $42.41 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $31.54 | 2025 | Libtayo |
| Nabriva Therapeutics, Plc | $28.76 | 2022 | |
| Allergan, INC. | $27.33 | 2019 | |
| Mayne Pharma Commercial LLC | $24.71 | 2022 | |
| Octapharma USA, INC. | $22.66 | 2021 | |
| Lnhc, INC | $22.22 | 2025 | Zelsuvmi |
| Convatec INC. | $20.80 | 2025 | |
| Ucb, INC. | $19.55 | 2025 | Bimzelx |
| Almirall LLC | $18.02 | 2019 | |
| Journey Medical Corporation | $14.78 | 2019 | |
| Sebela Pharmaceuticals INC. | $14.52 | 2022 | |
| Biofrontera INC. | $13.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Urbanek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.